Skip to main content
Sai Life Sciences Limited logo

Sai Life Sciences Limited — Investor Relations & Filings

Ticker · SAILIFE ISIN · INE570L01029 LEI · 335800JBS3NY25NIBC93 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 233 across all filing types
Latest filing 2026-01-28 Call Transcript
Country IN India
Listing BSE.NS SAILIFE

About Sai Life Sciences Limited

https://www.sailife.com

Sai Life Sciences Limited is a full-service Contract Research, Development, and Manufacturing Organization (CRO-CDMO) that partners with global pharmaceutical and biotechnology innovators to accelerate the discovery, development, and commercialization of complex small molecules. The company provides an integrated platform of services spanning discovery chemistry and biology, DMPK, toxicology, process development, analytical R&D, and commercial-scale manufacturing. With a focus on operational excellence and regulatory compliance, it operates state-of-the-art R&D and manufacturing facilities. Its value proposition centers on the Sai Nxt initiative, which emphasizes investments in advanced technologies, expanded capacity, and a global delivery model designed to reduce time-to-market for novel therapeutics.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is an intimation about the schedule of an earnings conference call for Sai Life Sciences Limited, specifically for discussing the unaudited financial results for the third quarter and nine months ended 31 December 2025. It includes details about the date, time, dial-in numbers, and management participants for the call. The document does not contain actual financial results or detailed financial statements but rather announces the upcoming earnings call event. According to the classification rules, such a document is best classified as a Call Transcript (CT) if it contains the full transcript, but here it is only an announcement of the call schedule, not the transcript itself. It is also not a report publication announcement (RPA) because it does not mention a report being attached or published. The document is an announcement of an earnings conference call, which aligns with the category of Call Transcript (CT) as it relates to earnings calls, even though it is only the schedule notice. Given the content, the best fit is Call Transcript (CT) with moderate confidence because it is related to the earnings call but does not contain the transcript itself.
2026-01-28 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-22 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice from Sai Life Sciences Limited informing stock exchanges about an upcoming Board Meeting scheduled for 5th February 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended 31 December 2025. The notice also mentions the closure of the trading window in compliance with insider trading regulations. The document is short (2011 characters) and serves as an announcement of a future event (Board Meeting) rather than containing any financial results or detailed reports itself. It does not contain actual financial data or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Interim Report or Earnings Release.
2026-01-22 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate submitted under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. It is a compliance certificate from the Registrar and Share Transfer Agent certifying details of securities dematerialized/rematerialized during the quarter. The document is addressed to stock exchanges and is a formal attestation rather than a financial report or announcement of financial results. It is short (3796 characters) and primarily serves as a regulatory compliance filing. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a certification and compliance document rather than a financial report or announcement.
2026-01-12 English
General Updates
Regulatory Filings
2026-01-07 English
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about an order passed by a tax authority related to GST demand and penalty. The document includes details of the order, the authority, the nature of the action, and the company's assessment of the impact. It is addressed to stock exchanges and is a regulatory disclosure about a material event affecting the company. The document is relatively short (3958 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement about a legal/tax matter but does not qualify as a full Legal Proceedings Report (LTR) since it is a regulatory disclosure under SEBI Listing Regulations. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-12-31 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.